| Lymphoma, Follicular
Brukinsa vs Yescarta
Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.Deep comparison between: Brukinsa vs Yescarta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYescarta has a higher rate of injection site reactions vs Brukinsa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yescarta but not Brukinsa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Brukinsa
Yescarta
At A Glance
Oral
Once or twice daily
BTK inhibitor
IV infusion
Single infusion
CD19-directed CAR T cell immunotherapy
Indications
- Mantle cell lymphoma
- Waldenstrom Macroglobulinemia
- Marginal Zone B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoma, Follicular
- Diffuse Large B-Cell Lymphoma
- Mediastinal (Thymic) Large B-Cell Lymphoma
- High grade B-cell lymphoma
- Lymphoma, Follicular
Dosing
Mantle cell lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 160 mg orally twice daily or 320 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Lymphoma, Follicular 160 mg orally twice daily in combination with obinutuzumab, with or without food, until disease progression or unacceptable toxicity.
Diffuse Large B-Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, High grade B-cell lymphoma Target dose 2 x 10^6 CAR-positive viable T cells per kg body weight (max 2 x 10^8 cells) as a single IV infusion; pretreat with cyclophosphamide 500 mg/m2 IV and fludarabine 30 mg/m2 IV on days -5, -4, and -3 before infusion.
Lymphoma, Follicular Target dose 2 x 10^6 CAR-positive viable T cells per kg body weight (max 2 x 10^8 cells) as a single IV infusion; pretreat with cyclophosphamide 500 mg/m2 IV and fludarabine 30 mg/m2 IV on days -5, -4, and -3 before infusion.
Contraindications
—
—
Adverse Reactions
Most common (>=30%) Neutrophil count decreased, platelet count decreased, upper respiratory tract infection, hemorrhage, musculoskeletal pain
Serious Hemorrhage, pneumonia, cytopenias, second primary malignancies, cardiac arrhythmias, hepatotoxicity including drug-induced liver injury
Postmarketing Drug-induced liver injury
Most common (>=30%) CRS, fever, hypotension, encephalopathy, fatigue, tachycardia, headache, nausea, febrile neutropenia, diarrhea, musculoskeletal pain, infections with pathogen unspecified, chills, decreased appetite
Serious CRS, fever, encephalopathy, hypotension, infection with unspecified pathogen, pneumonia, febrile neutropenia, cardiac arrhythmia, cardiac failure, aphasia, hypoxia
Postmarketing Spinal cord edema, myelitis, quadriplegia, dysphagia, status epilepticus, infusion related reactions, T cell malignancies
Pharmacology
Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) that forms a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK activity and thereby blocking B-cell proliferation, trafficking, chemotaxis, and adhesion pathways driven by B-cell antigen receptor and cytokine receptor signaling.
CD19-directed genetically modified autologous T cell immunotherapy; upon engagement with CD19-expressing target cells, the CD28 and CD3-zeta co-stimulatory domains activate downstream signaling cascades leading to T cell activation, proliferation, and killing of CD19-expressing cancer cells and normal B cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Brukinsa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Yescarta
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Brukinsa
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (4/8)
Yescarta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Brukinsa
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Yescarta
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Brukinsa.
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BrukinsaView full Brukinsa profile
YescartaView full Yescarta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.